Men are at higher risk for metabolic dysfunction-associated steatotic liver disease (MASLD) with clinically significant fibrosis (CSF) than premenopausal women, but data are lacking in persons with HIV (PWH). The aim of this study was to discover prevalence and severity of MASLD in PWH by sex assigned at birth and menopausal status.MethodsWe examined participants from the prospective, cross-sectional HIV NASH CRN who had suppressed HIV-1 RNA, self-reported sex assigned at birth and menopause status, and underwent transient elastography (TE). The primary outcome was MASLD (controlled attenuation parameter [CAP] ≥ 263 dB/m, ≥1 cardiometabolic risk factor, Alcohol Use Disorders Identification Test score <8) with CSF (MASLD-CSF, TE Liver Stiffness Measurement ≥ 8 kPa).ResultsNine hundred and sixty-four PWH were included: 709 men (73.5%) and 255 women (26.5%) with similar median ages (55.1 and 56.6 years, P-value = .08). The most common race was Black (52%). Women had lower prevalence of MASLD-CSF than men (5.5% vs 10.6%, P = .02). In a multivariable logistic regression model for MASLD-CSF, diabetes (OR 3.26 [95% confidence interval 2.01–5.30], P < .0001), hyperlipidemia (1.97 [1.14–3.39], P = .02), and waist circumference (WC) above sex-specific cutoff (women: 80 cm, men: 94 cm) (4.59 [2.12–9.93], P < .0001) were associated with higher odds of MASLD-CSF, while female sex was associated with lower odds (0.43 [0.23–0.81], P = .01). Variables and effect sizes associated with MASLD-CSF differed among sex/menopause subgroups.ConclusionsFemale sex was protective against MASLD-CSF in PWH. Men with diabetes, hyperlipidemia, and high WC would be candidates for MASLD screening. Further studies of PWH with women, especially more young women, are needed.

Patients with PBC and hyperlipidemia had significantly higher rates of cardiovascular and metabolic outcomes.

CorrectSequence Therapeutics has unveiled the first gene editing treatment targeting APOC3 to combat hyperlipidemia, marking a major milestone in medical biotechnology.

Hospitalization causes among persons with HIV (PWH) have shifted to non-AIDS conditions, but the complete disease profile of hospitalized PWH has not been well described. To inform hospitalization and readmission prevention efforts, we examined non-AIDS disease prevalence among PWH hospitalized in 4 US cohorts and 1 Canadian cohort.MethodsAmong PWH with ≥1 hospitalization from 2008 to 2018, we used log-binomial regression with generalized estimating equations to estimate trends in the annual prevalence of hepatitis B virus (HBV), hepatitis C virus (HCV), hypertension, hyperlipidemia, diabetes mellitus, chronic kidney disease (CKD) stage ≥3, and multimorbidity (≥2 and ≥3 conditions), defined using longitudinal diagnosis, medication, and laboratory data.ResultsWe examined 6781 hospitalized PWH who were 75% cisgender men, 40% White, and 38% Black. From 2008 to 2018, the proportion of PWH in care who had ≥1 hospitalization decreased from 9.6% to 6.3%. Age- and cohort-adjusted prevalence increased for hyperlipidemia (relative change per year: 3.6% [95% CI: 2.5%–4.7%]), diabetes mellitus (2.8% [1.3%–4.4%]), CKD (3.3% [1.7%–4.9%]), ≥2 conditions (1.3% [0.6%–2.0%]), and ≥3 conditions (3.0% [1.7%–4.3%]), decreased for HCV infection (−2.0% [−3.0%, −0.9%]), and remained stable for HBV infection (1.6% [−1.1%, 4.3%]) and hypertension (0.4% [−0.2%, 1.1%]).ConclusionsHospitalized PWH had an increasing burden of several non-AIDS conditions and multimorbidity not accounted for by aging alone. Further work is needed to understand these conditions’ role in hospitalization risk among PWH. Our findings reinforce that hospital discharge planning in PWH should include efforts to ensure chronic conditions are adequately managed.

CorrectSequence Therapeutics has achieved a groundbreaking milestone by successfully administering the first-ever gene-editing therapy targeting APOC3 for hyperlipidemia patients. This innovation could mean a significant shift in treatment protocols.

CorrectSequence Therapeutics announces a groundbreaking gene-editing treatment targeting APOC3 for hyperlipidemia, marking a significant medical milestone.

CorrectSequence Therapeutics has made a historic innovation by administering the first gene-editing therapy aimed at treating hyperlipidemia. Learn more about this groundbreaking advancement.

CorrectSequence Therapeutics introduces the world's first gene-editing therapy targeting APOC3, marking a significant breakthrough in hyperlipidemia treatment.

Recent findings reveal that pregnant women with high cholesterol may face serious cardiovascular risks and complications during and after pregnancy.

Treatment IC7Fc targets hepatic regulation of lipid metabolism and inflammation, ameliorating atherosclerosis in mice.

Treatment IC7Fc targets hepatic regulation of lipid metabolism and inflammation, ameliorating atherosclerosis in mice.

Objectives: This study aimed to evaluate the impact of pre-existing cardiovascular disease (CVD) and dyslipidemia on mortality in patients undergoing continu...